These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 1384920)
1. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Miller PD; Eardley I; Kirby RS Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920 [TBL] [Abstract][Full Text] [Related]
2. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240 [TBL] [Abstract][Full Text] [Related]
3. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Ataus S; Citçi A; Alici B; Onder AU; Sönmezoğlu K; Erözenci A; Solok V Int Urol Nephrol; 1999; 31(4):481-9. PubMed ID: 10668943 [TBL] [Abstract][Full Text] [Related]
4. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Bruwer G; Heyns CF; Allen FJ Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624 [TBL] [Abstract][Full Text] [Related]
5. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394 [TBL] [Abstract][Full Text] [Related]
6. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Lorente JA; Valenzuela H; Morote J; Gelabert A Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948 [TBL] [Abstract][Full Text] [Related]
7. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Pantelides ML; Bowman SP; George NJ Br J Urol; 1992 Sep; 70(3):299-303. PubMed ID: 1384921 [TBL] [Abstract][Full Text] [Related]
8. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Huncharek M; Muscat J Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590 [TBL] [Abstract][Full Text] [Related]
9. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Lee CT; Oesterling JE Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236 [TBL] [Abstract][Full Text] [Related]
10. [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups]. Rusu D; Rusu V; Stefănescu C; Rusu M; Răileanu I; Stătescu AM Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):476-83. PubMed ID: 20700990 [TBL] [Abstract][Full Text] [Related]
11. Is bone scintigraphy necessary in initial staging of prostate cancer patients? Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013 [TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Huncharek M; Muscat J Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585 [TBL] [Abstract][Full Text] [Related]
13. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer? Perachino M; Di Ciolo L; Barbetti V; Puppo P Eur Urol; 1996; 29(3):366-9. PubMed ID: 8740025 [TBL] [Abstract][Full Text] [Related]
14. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734 [TBL] [Abstract][Full Text] [Related]
15. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870 [TBL] [Abstract][Full Text] [Related]
16. PSA and bone scintigraphy. Modoni S; Calò E; Nardella G; Ritrovato G; Frusciante V Int J Biol Markers; 1997; 12(4):158-61. PubMed ID: 9582605 [TBL] [Abstract][Full Text] [Related]
17. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119 [TBL] [Abstract][Full Text] [Related]
18. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer. Singh OP; Yogi V; Redhu P; Ghori HU; Pareek A; Lal N J Cancer Res Ther; 2019 Mar; 15(Supplement):S39-S41. PubMed ID: 30900618 [TBL] [Abstract][Full Text] [Related]
19. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort. KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247 [TBL] [Abstract][Full Text] [Related]
20. Retrospective study of predictors of bone metastasis in prostate cancer cases. Ho CC; Seong PK; Zainuddin ZM; Abdul Manaf MR; Parameswaran M; Razack AH Asian Pac J Cancer Prev; 2013; 14(5):3289-92. PubMed ID: 23803117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]